Cite
HARVARD Citation
Vallejo-Vaz, A. et al. (2022). Residual risk of major adverse cardiovascular and limb events among different atherosclerotic cardiovascular disease phenotypes receiving guideline-recommended antiplatelet monotherapy: The resrisk study. Atherosclerosis. pp. 31-. [Online].